DGAP-Adhoc: Ad hoc Announcement Pursuant to § 15 WpHG (German Securities Trading Act): Epigenomics AG secures financing of up to EUR 5m

Epigenomics AG / Key word(s): Corporate Action

18.08.2013 20:20

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Berlin, Germany, August 18, 2013 - Epigenomics AG (ISIN: DE000A1K0516)
announces that it has entered into an agreement with YA Global Master SPV
Ltd. through which it secured a convertible bond financing for up to EUR
5m. Under the terms of the agreement, YA Global Master SPV Ltd., over a
period of up to two years, is obliged to purchase convertible notes with a
total nominal amount of EUR 5m at a purchase price of 95% of the nominal
amount. Epigenomics may issue the convertible notes in tranches of EUR
500,000 each at its sole discretion. A tranche comprises 500 convertible
notes in the form of bearer bonds each with a nominal value of EUR 1,000
and transferrable only upon approval of Epigenomics. The convertible notes
will only be issued and may only be traded in lots with a total nominal
value of EUR 125,000.

The bonds carry no interest, have a term of nine months and are convertible
into shares of Epigenomics immediately upon issuance at the discretion of
the bearer of the bonds. The conversion price equals the average trading
price of Epigenomics shares during a 5 day period prior to the time of
conversion less a 5% discount, but cannot be lower than 80% of the
prevailing share price at the time of the issuance of the convertible
bonds.

To the extent permitted by the existing authorization of Epigenomics'
General Shareholders' Meeting, the bonds will be issued without pre-emptive
rights to existing shareholders. Currently Epigenomics has the
authorization to issue convertible bonds that may be converted into up to
1,196,783 shares without offering those pre-emptive rights. Further
convertible bonds resulting in the issuance of up to an additional
3,933,217 shares may be issued with pre-emptive rights to existing
shareholders.

Epigenomics expects that the proceeds from the issuance of these bonds will
help to fund the business operations up to and possibly beyond the FDA
approval of its lead product, Epi proColon(R), a blood-based test for the
detection of colorectal cancer.

- End of Ad hoc -

Contact Epigenomics AG

Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386

ir@epigenomics.com
www.epigenomics.com

Epigenomics' legal disclaimers. This communication expressly or implicitly
contains certain forward-looking statements concerning Epigenomics AG and
its business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Epigenomics AG is
providing this communication as of this date and does not undertake to
update any forward-looking statements contained herein as a result of new
information, future events or otherwise.

The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.

---------------------------------------------------------------------------

Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart

End of Announcement DGAP News-Service

---------------------------------------------------------------------------